The Viennese start-up Proxygen has recently announced its collaboration with MSD, a US pharmaceutical group, which will invest up to 2.3 billion euros in the young Austrian biotech company, a spin-off of the Austrian Academy of Sciences, over the next few years. In return, Proxygen plans to develop so-called “molecular glue degraders” for medical applications […] Continue reading ““The most important thing is to encourage curiosity””